AronssonA., BygdemanM., Gemzell-DanielssonK.Effects of misoprostol on uterine contractility following different routes of administration. Human Reprod2004; 19: 81–84.
2.
BygdemanM.Pharmacokinetics of prostaglandins. Best Pract Res Clin Obstet Gynaecol2003; 17: 707–716.
3.
JohnstonA.Estrogens: pharmacokinetics and pharmacodynamics with special reference to vaginal administration and the new estradiol formulation Estring. Acta Obstet et Gynecol Scand1996; 163: 16–25.
4.
OwenD.H., DunmireE.N., PlanysA.M., KatzD.F.Factors influencing nonoxynol-9 permeation and bioactivity in cervical mucus. J Control Release1999; 60: 23–34.
5.
QuanM.Vaginitis: meeting the clinical challenge. Clin Cornerstone2000; 31: 36–47.
6.
CeschelG.C., MaffeiP., Lombardi BorgiaS., RonchiC., RossiS.Development of a mucoadhesh/e dosage form for vaginal administration. Drug Dev Ind Pharm2001; 27: 541–547.
7.
WoolfsonD.A., MalcolmR.K., GallagherR.Drug delivery by the intravaginal route. Crit Rev Ther Drug Carrier Syst2000; 17: 509–555.
8.
OstropN.J., LambJ., ReidG.Intravaginal morphine: an alternative route of administration. Pharmacotherapy1998; 18: 863–865.
9.
MuijsersR.B., WagstaffA.J.Transdermal fentanyl: an updated review of its pharmacological properties and therapeutic efficacy in chronic cancer pain control. Drugs2001; 61: 2289–2307.
10.
RobisonJ.M., WilkieD.J., CampbellB.Sublingual and oral morphine administration: review and new findings. Nurs Clin North Am1995; 30: 725–743.
LennernasB., HednerT., HolmbergM., BredenbergS., NystromC., LennernasH.Pharmacokinetics and tolerability of different doses of fentanyl following sublingual administration of a rapidly dissolving tablet to cancer patients: a new approach to treatment of incident pain. Br J Clin Pharmacol2005; 59: 249–253.
13.
FarrarJ.T., ClearyJ., RauckR., BuschM.D., NordbrockE.Oral transmucosal fentanyl citrate: a randomized, double-blind, placebo-controlled trial for the treatment of breakthrough pain in cancer patients. J Natl Cancer Inst1998; 90: 611–616.
14.
PortenoyR.K., PayneR., ColuzziP., RaschkoJ.W., LyssA., BuschM.A.Oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients: a controlled dose titration study. Pain1999; 79: 303–312.
15.
EganT.D., SharmaA., AshburnM.A., KievitJ., PaceN.L., StatM., StreisandJ.B.Multiple dose pharmacokinetics of oral transmucosal fentanyl citrate in healthy volunteers. Anesthesiology2000; 92: 665–673.
16.
The Extra Pharmacopoeia by Martindale.32nd edition.Pharmaceutical Press: London, 1999
